AskBio Launches AskFirst™ Patient Advocacy Program to Educate and Support Participants in Gene Therapy Clinical Trials
29 janv. 2020 10h27 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, today introduced...
Visiongain launches new report on Gene Therapy R&D and Revenue Forecasts 2018-2028
05 sept. 2018 12h33 HE
|
Visiongain Ltd
LONDON, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Gene Therapy Market set to Grow at a CAGR of 41.1% in the first half of the forecast period. Visiongain has launched a new pharma report: Gene Therapy...
Metabolon Launches Meta UDx™ Test to Speed Diagnosis of Rare and Undiagnosed Diseases in Children and Adults
28 févr. 2018 10h50 HE
|
Metabolon, Inc.
Meta UDx provides in-depth metabolic information and new insights for difficult-to-diagnose patient cases Expanding LDT clinical testing portfolio demonstrates value of clinical metabolomics for...
APHL Announces Newborn Screening Funding Recipients
19 déc. 2017 10h41 HE
|
Association of Public Health Labs
Silver Spring, MD, Dec. 19, 2017 (GLOBE NEWSWIRE) -- For Immediate Release The Association of Public Health Laboratories (APHL) is pleased to announce the recipients of the second round of New...
Metabolon Launches Meta IMD™ Test to Speed Diagnosis of Inherited Metabolic Disorders
28 sept. 2016 10h05 HE
|
Metabolon, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Metabolon, Inc., the global leader in metabolomics, announced today that Meta IMD™ is now available to physicians as a CLIA...
EPIRUS Announces Reprioritization of Pipeline to Solely Focus on Biosimilars to Treat Rare Diseases and Key Leadership Changes
09 mai 2016 16h00 HE
|
EPIRUS Biopharmaceuticals, Inc.
New strategy to focus exclusively on BOW080 (eculizumab biosimilar) and BOW070 (tocilizumab biosimilar) in rare diseases with a combined target market opportunity of close to $6 billion of innovator...
BioMarin Receives Orphan Drug Designation From FDA for First AAV-Factor VIII Gene Therapy, BMN 270, for Patients With Hemophilia A
01 mars 2016 17h42 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BMN 270, an investigational gene therapy for the treatment of patients with...
BioMarin Announces BioMarin RareConnections(TM) Rebranding and Consolidating BioMarin’s Comprehensive Support and Services for Eligible Rare Disease Patients
29 févr. 2016 08h30 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the launch of BioMarin RareConnectionsTM, rebranding its patient-focused offering...
BioMarin Announces 21 Presentations at 12th Annual WORLDSymposium™ 2016 February 29-March 4 in San Diego, California: 6 Oral and 15 Poster
29 févr. 2016 08h25 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company will present data in six oral and 15 poster presentations at the...
Actress Patricia Richardson and NORD Join Together to Make a Difference on Rare Disease Day
25 févr. 2014 08h00 HE
|
National Organization for Rare Disorders
DANBURY, CT--(Marketwired - Feb 25, 2014) - Millions of Americans will participate in events across the country on February 28 as part of the 6th annual U.S. Rare Disease Day. These activities are...